Effect of Anacetrapib on Cholesterol Efflux Capacity: A Substudy of the DEFINE Trial

BACKGROUND: Anacetrapib is the only cholesteryl ester transfer protein inhibitor proven to reduce coronary heart disease (CHD). However, its effects on reverse cholesterol transport have not been fully elucidated. Macrophage cholesterol efflux (CEC), the initial step of reverse cholesterol transport...

Descripción completa

Detalles Bibliográficos
Autores principales: Metzinger, Mark P., Saldanha, Suzanne, Gulati, Jaskeerat, Patel, Kershaw V., El‐Ghazali, Ayea, Deodhar, Sneha, Joshi, Parag H., Ayers, Colby, Rohatgi, Anand
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7955402/
https://www.ncbi.nlm.nih.gov/pubmed/33263263
http://dx.doi.org/10.1161/JAHA.120.018136

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7955402/
https://www.ncbi.nlm.nih.gov/pubmed/33263263
http://dx.doi.org/10.1161/JAHA.120.018136

Ejemplares similares